BPC-157 10mg + TB-500 10mg (10mg + 10mg)
High-concentration co-lyophilized dual-peptide vial combining 10 mg BPC-157 and 10 mg TB-500 (20 mg total active peptide), verified via dual-peak RP-HPLC integration for synergistic tissue-repair research models.
Scientific Profile & Research Key Points: BPC-157 10mg + TB-500 10mg
High-concentration co-lyophilized dual-peptide vial combining 10 mg BPC-157 and 10 mg TB-500 (20 mg total active peptide), verified via dual-peak RP-HPLC integration for synergistic tissue-repair research models.
Active Batch Release Specifications (Lot SL-2026-111)
Analytical release verification for current BPC-157 10mg + TB-500 10mg (10mg + 10mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-111 | 2026-10-28 | Gradient RP-HPLC (Multi-Peak Resolution) + ESI-MS | ≥99.0% (Resolved Constituent Peaks) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile 0.9% Bacteriostatic Water (2.0–3.0 mL); swirl gently without vortexing
Temperature & Stability
Store lyophilized blend at -20°C. Store reconstituted solution at 2°C–8°C and use within 28 days.
BPC-157 10mg + TB-500 10mg — Technical Questions & Answers
How are the individual constituents of BPC-157 10mg + TB-500 10mg verified in a single vial?
Because co-lyophilized blends contain multiple sequences with distinct retention times, Lot SL-2026-111 is evaluated via gradient RP-HPLC to resolve each constituent peak independently, paired with ESI-MS mass confirmation (1419.53 g/mol & 4963.50 g/mol).
How do you calculate working stock aliquots for a multi-component blend like BPC-157 10mg + TB-500 10mg?
Calculate each active constituent separately based on its labeled mass ratio (10mg + 10mg) divided by total diluent volume added. For example, adding 2.0 mL of sterile diluent yields proportional mg/mL concentrations for every component simultaneously.
What primary pathways are investigated using BPC-157 10mg + TB-500 10mg?
Investigators study BPC-157 10mg + TB-500 10mg in Dual VEGFR2/NO angiogenesis & G-actin sequestration pathways models. Primary published literature context: Sikiric P. et al., Curr Pharm Des (2018) & Goldstein A.L. et al., Expert Opin Biol Ther (2012) — Complementary angiogenic and actin-remodeling models. All lots are supplied strictly for in-vitro laboratory experimentation.
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
BPC-157 vs TB-500 vs KPV: Tendon Repair, Actin & Inflammatory Pathways
A comparative analysis of Body Protection Compound-157 (pentadecapeptide) and Thymosin Beta-4 active fragment TB-500. Differences in VEGF signaling, actin sequestration, and combined laboratory models.
TB-500 (Thymosin β4): Actin Regulation, Cell Motility, and Angiogenesis in Wound Repair
A biochemical review of Thymosin Beta-4 and its synthetic sequence TB-500. G-actin monomer sequestering, cell migration, down-regulation of inflammation, and HPLC analysis.
How to Read a Peptide Certificate of Analysis (COA): Step-by-Step Breakdown
A practical guide for researchers. How to analyze HPLC chromatograms, verify retention time, interpret mass spec m/z peaks, evaluate counterion salt ratios, and spot fraudulent documents.
Related Recovery & Tissue Repair Compounds
View category →